Literature DB >> 12454041

Immunity to lysostaphin and its therapeutic value for ocular MRSA infections in the rabbit.

Joseph J Dajcs1, Brett A Thibodeaux, Dalia O Girgis, Megan D Shaffer, Stephen M Delvisco, Richard J O'Callaghan.   

Abstract

PURPOSE: To determine the effects of immunization against lysostaphin on the bactericidal action of lysostaphin in ocular tissue and the possible induction of allergic reactions.
METHODS: Rabbits were immunized against lysostaphin by subcutaneous, intranasal, or topical routes. Anti-lysostaphin antibody titers were determined by ELISA and by neutralization of lysostaphin. Methicillin-resistant Staphylococcus aureus was intrastromally or intravitreously injected into rabbit eyes. Eyes were treated either topically with drops of lysostaphin (0.3%) or with a single intravitreous injection (0.1 mL) of lysostaphin (0.1%). At the time of death, corneas or vitreous humors were cultured to determine the number of colony forming units (CFU).
RESULTS: Rabbits in keratitis experiments that were immunized subcutaneously, intranasally, or topically had serum antibody titers of 10,240, 187, and 1,867, respectively, and neutralization titers of 8 or less. In both normal and immunized rabbits with keratitis, lysostaphin significantly reduced the log CFU to less than 1 log, whereas the untreated eyes contained more than 10(6) CFU/cornea (P < or = 0.0001). Rabbits that were subcutaneously or topically immunized for endophthalmitis experiments had serum antibody titers of 1636 or 137, respectively, and neutralization titers of 2 or less. A single intravitreous injection of lysostaphin (0.1%) sterilized all eyes of immunized and nonimmune rabbits with endophthalmitis. No adverse effects were observed with the administration of lysostaphin to either normal or immunized rabbit eyes.
CONCLUSIONS: Lysostaphin treatment of immunized rabbits was effective in treating S. aureus-infected eyes, despite the presence of anti-lysostaphin antibody. No adverse reactions were produced by administration of lysostaphin to immunized rabbits.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12454041

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  20 in total

1.  A novel chimeric lysin shows superiority to mupirocin for skin decolonization of methicillin-resistant and -sensitive Staphylococcus aureus strains.

Authors:  Mina Pastagia; Chad Euler; Peter Chahales; Judilyn Fuentes-Duculan; James G Krueger; Vincent A Fischetti
Journal:  Antimicrob Agents Chemother       Date:  2010-11-22       Impact factor: 5.191

2.  Staphylococcus aureus biofilm as a target for single or repeated doses of oxacillin, vancomycin, linezolid and/or lysostaphin.

Authors:  E Walencka; B Sadowska; S Rózalska; W Hryniewicz; B Rózalska
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.099

3.  Electrostatic-Mediated Affinity Tuning of Lysostaphin Accelerates Bacterial Lysis Kinetics and Enhances In Vivo Efficacy.

Authors:  Hongliang Zhao; Susan Eszterhas; Jacob Furlon; Hao Cheng; Karl E Griswold
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

4.  Deimmunized Lysostaphin Synergizes with Small-Molecule Chemotherapies and Resensitizes Methicillin-Resistant Staphylococcus aureus to β-Lactam Antibiotics.

Authors:  Yongliang Fang; Jack R Kirsch; Liang Li; Seth A Brooks; Spencer Heim; Cynthia Tan; Susan Eszterhas; Hao D Cheng; Hongliang Zhao; Yan Q Xiong; Karl E Griswold
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

5.  Lysostaphin Lysibody Leads to Effective Opsonization and Killing of Methicillin-Resistant Staphylococcus aureus in a Murine Model.

Authors:  Assaf Raz; Anna Serrano; Maneesha Thaker; Tricia Alston; Vincent A Fischetti
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

6.  Organ injury and cytokine release caused by peptidoglycan are dependent on the structural integrity of the glycan chain.

Authors:  Anders E Myhre; Jon Fredrik Stuestøl; Maria K Dahle; Gunhild Øverland; Christoph Thiemermann; Simon J Foster; Per Lilleaasen; Ansgar O Aasen; Jacob E Wang
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

7.  Evaluation of Pseudomonas aeruginosa staphylolysin (LasA protease) in the treatment of methicillin-resistant Staphylococcus aureus endophthalmitis in a rat model.

Authors:  Irina S Barequet; Zohar Habot-Wilner; Oran Mann; Mary Safrin; Dennis E Ohman; Efrat Kessler; Mordechai Rosner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-03-12       Impact factor: 3.117

8.  Pseudomonas aeruginosa LasA protease in treatment of experimental staphylococcal keratitis.

Authors:  Irina S Barequet; Guy J Ben Simon; Mary Safrin; Dennis E Ohman; Efrat Kessler
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

9.  Crystal structure of a putative lysostaphin peptidase from Vibrio cholerae.

Authors:  Sugadev Ragumani; Desigan Kumaran; Stephen K Burley; Subramanyam Swaminathan
Journal:  Proteins       Date:  2008-08-15

10.  Influence of antidrug antibodies on plectasin efficacy and pharmacokinetics.

Authors:  Karoline Sidelmann Brinch; Niels Frimodt-Møller; Niels Høiby; Hans-Henrik Kristensen
Journal:  Antimicrob Agents Chemother       Date:  2009-08-17       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.